Article Text

other Versions

PDF
Vardenafil therapy for patients with pulmonary arterial hypertension. A one-year, multicentre, open-label study
  1. Zhi-Cheng Jing (jingzhicheng{at}gmail.com)
  1. Department of Pulmonary Circulation,Shanghai Pulmonary Hospital, China
    1. Xin Jiang (jxcs983{at}163.com)
    1. Department of Pulmonary Circulation,Shanghai Pulmonary Hospital, China
      1. Bing-Xiang Wu
      1. Department of Cardiology, First Affiliated Hospital, Haerbin Medical University, Haerbin, China
        1. Xi-Qi Xu (xuxiqi0928{at}yahoo.com.cn)
        1. Department of Internal Medicine, Aviation Industry Central Hospital, Beijing, China
          1. Yan Wu (yanr{at}tiaoqiang.com)
          1. Department of Cardiovascular Medicine, Cardiovascular Institute and Fu Wai Hospital,Beijing, China
            1. Chuan-Rong Ma
            1. Department of Pulmonary Circulation,Shanghai Pulmonary Hospital, China
              1. Yong Wang
              1. Department of Respiratory Medicine, Beijing Shijitan Hospital, Peking University, Beijing, China
                1. Yue-Jin Yang
                1. Department of Cardiovascular Medicine, Cardiovascular Institute and Fu Wai Hospital,Beijing, China
                  1. Jie-Lin Pu
                  1. Department of Cardiovascular Medicine, Cardiovascular Institute and Fu Wai Hospital,Beijing, China
                    1. Wen Gao
                    1. Department of Thoracic Surgery,Shanghai Pulmonary Hospital, China

                      Abstract

                      Background: Vardenafil is a new phosphodiesterase-5 (PDE5) inhibitor that has shown some efficacy in the treatment of pulmonary arterial hypertension (PAH). As yet, however, no large clinical studies examining its long-term effects in patients with PAH have been conducted.

                      Methods: A multicentre, open-label study of one-year's duration was undertaken in 45 patients with PAH to determine the long-term safety and efficacy of vardenafil (5 mg once daily for the first 4 weeks, then 5 mg twice daily) and make a preliminary assessment of its monthly acquisition cost versus other PAH-active therapies. The patients' clinical features, exercise capacity, WHO functional class, and haemodynamic variables were measured at baseline and at 3 and at least 9 months after initiating vardenafil therapy.

                      Results: At the 3 months and 14 ± 3 months (range, 9 to 18 months) follow-up assessments, the 6-minutes walking distance (6MWD) was significantly increased from baseline by 70.7 ± 78.4 metres (p <0.0001) and 83.4 ±91.8 metres (p <0.0001), respectively. Furthermore, long-term treatment with vardenafil for a mean duration more than one year was also associated with improvements in haemodynamic parameters, WHO functional class and serum uric acid concentrations. Overall, vardenafil treatment was well tolerated. No patients were withdrawn due to adverse events, and none died during the course of the study.

                      Conclusion: Long-term treatment with vardenafil is well tolerated and has sustained beneficial effects on PAH, as measured by patients¡¯ exercise capacity, WHO functional class, and haemodynamic parameters.

                      Statistics from Altmetric.com

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.